What we do Fermenta Biotech Limited specializes in manufacturing and marketing Active Pharmaceutical Ingredients, biotechnology products, environmental solutions, and renting properties globally. |
Founded in 1,951 |
Market share Market leader in Vitamin D3 and nutritional ingredients with a global presence across 60+ countries serving 400+ customers. |
Problem solved Provides science-backed nutritional ingredients and eco-friendly biotech solutions addressing global health, preventive care, and environmental challenges. |
Top clients or who we serve Serves pharmaceutical, dietary supplements, food and beverage, veterinary, and animal feed industries globally (B2B focus). |
Key management Executive Vice-Chairman Mr. Krishna Datla, Managing Director Mr. Prashant Nagre; known for leadership in biotech and pharmaceuticals. |
Our journey and innovations Established collaborations since 1950s; expanded from pharmaceuticals to vitamin D3, biotechnological enzymes, premixes; patented key Vitamin D3 technologies; ongoing R&D in enzymatic synthesis. |
Where we operate India, Europe (Germany, UK), USA, and other international markets with manufacturing facilities and subsidiaries. |
Top products or what we offer Vitamin D3 variants for human and animal nutrition, Active Pharmaceutical Ingredients (APIs), green chemistry enzymes, fortified food premixes, and environmental biotech solutions. |
Top brands Vitamin D3 (Human & Animal Nutrition) - market leader; Fermase PA 850 enzyme; Fortified Rice Kernel (FRK); VITADEE plant-based Vitamin D3. |
Raw materials needed Cholesterol and phytosterols for Vitamin D3 production, enzymes for biotechnological processes, chemical intermediates. |
Raw materials supplier Suppliers not explicitly mentioned; likely global chemical and raw material providers maintaining quality standards. |
Recurring vs cyclical contribution Revenue mainly recurring from long-term contracts in nutrition and biotech, with some cyclical exposure in real estate leasing. |
Our industry position Strong position in global nutrition ingredients, with state-of-the-art manufacturing and validated products meeting global regulatory standards. |
Financial highlights FY2024-25 consolidated revenue INR 481 crores; profit INR 76.4 crores; 25% revenue growth year-on-year; improving profitability trajectory. |
Geographical revenue split India 39%, Europe 32%, USA 13%, Others 16% of consolidated revenue excluding real estate income. |
Order book - |
Whats driving growth Increasing demand in human and animal nutrition, growing health awareness, food fortification initiatives, and expanding global markets. |
Our future plans Expansion of manufacturing capacity, new product launches including advanced vitamin formulations, and scaling environmental biotech offerings. |
Our green promise Development of plant-based Vitamin D3, green chemistry processes, and biotech solutions aimed at environmental sustainability. |
Our people and values 606 employees fostering innovation, diversity, strong governance, and a safe work environment with comprehensive compliance programs. |
Key challenges ahead Regulatory changes, competition in nutritional ingredients, raw material cost volatility, and managing diversification. |
Interesting facts Over 75 years of expertise; pioneering patented enzymatic synthesis for key drugs; global certifications including USFDA, EU GMP; strong R&D pipeline. |
Risks and strategy Mitigates regulatory and market risks through diversified product offerings, strategic partnerships, and robust internal controls. |
